Skip to Content
Merck
All Photos(1)

Key Documents

View All Documentation

O-004

Supelco

Oxymorphone solution

1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C17H19NO4
CAS Number:
76-41-5
Molecular Weight:
301.34
MDL number:
MFCD00079194
UNSPSC Code:
41116107
PubChem Substance ID:
329818813
NACRES:
NA.24

grade

certified reference material

Quality Level

300

form

liquid

feature

Snap-N-Spike®/Snap-N-Shoot®

packaging

ampule of 1 mL

manufacturer/tradename

Cerilliant®

drug control

Narcotic Licence Schedule A (Switzerland); estupefaciente (Spain); Decreto Lei 15/93: Tabela IA (Portugal)

concentration

1.0 mg/mL in methanol

technique(s)

gas chromatography (GC): suitable
liquid chromatography (LC): suitable

application(s)

forensics and toxicology

format

single component solution

storage temp.

2-8°C

SMILES string

CN1CC[C@]23[C@H]4Oc5c(O)ccc(C[C@@H]1[C@]2(O)CCC4=O)c35

InChI

1S/C17H19NO4/c1-18-7-6-16-13-9-2-3-10(19)14(13)22-15(16)11(20)4-5-17(16,21)12(18)8-9/h2-3,12,15,19,21H,4-8H2,1H3/t12-,15+,16+,17-/m1/s1

InChI key

UQCNKQCJZOAFTQ-ISWURRPUSA-N

Gene Information

human ... OPRD1(4985) , OPRK1(4986) , OPRM1(4988)

Looking for similar products? Visit Product Comparison Guide

Related Categories

General description

A certified Snap-N-Spike® solution of oxymorphone suitable for use in a variety of GC/MS or LC/MS applications from pain prescription monitoring, clinical toxicology, and pharmaceutical research to forensic analysis and urine drug testing. Oxymorphone, sold under trade names such as Opana®, Numorphan®, and Numorphone, is an opiate analgesic indicated for the relief of moderate to severe pain.

Legal Information

CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
Numorphan is a registered trademark of Endo Pharmaceuticals Inc.
Opana is a registered trademark of Endo Pharmaceuticals Inc.
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany

related product

Product No.
Description
Pricing

P-071

Pain Management Multi-component Opiate Mixture-13 solution, 100 μg/mL each component (10 μg/mL Fentanyl), ampule of 1.0 mL, certified reference material, Cerilliant®

H-098

6α/β-Hydroxyoxymorphone-D3 solution, 100 μg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

N-012

Noroxymorphone hydrochloride solution, 1.0 mg/mL in methanol: DMSO (80:20) (as free base), ampule of 1 mL, certified reference material, Cerilliant®

O-003

Oxymorphone-D3 solution, 100 μg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

O-019

Oxymorphone-D3 solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

O-030

Oxymorphone-3-β-D-glucuronide solution, 100 μg/mL in methanol: water (1:1), ampule of 1 mL, certified reference material, Cerilliant®

O-031

Oxymorphone-D3-3-β-D-glucuronide solution, 100 μg/mL in methanol: water (1:1), ampule of 1 mL, certified reference material, Cerilliant®

O-004S

Oxymorphone solution, 1 mg/mL in methanol, certified reference material, ampule of 1 mL, Cerilliant®

Signal Word

Danger

Hazard Classifications

Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1

Target Organs

Eyes

Storage Class Code

3 - Flammable liquids

WGK

WGK 2

Flash Point(F)

49.5 °F - closed cup

Flash Point(C)

9.7 °C - closed cup

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documents section.

If you need assistance, please contact Customer Support.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Noam Y Kirson et al.
Journal of medical economics, 15(1), 87-95 (2011-10-29)
Compare direct and indirect costs of oxymorphone extended-release ('oxymorphone') and oxycodone controlled-release ('oxycodone') users. Patients, aged 18+, with ≥1 claim for oxymorphone/oxycodone, Q2:2006-Q4:2009, were selected from a de-identified private payer claims database and observed from the first such claim ('index
Suzanne K Vosburg et al.
Drug and alcohol dependence, 126(1-2), 206-215 (2012-06-23)
The extent of prescription opioid abuse has led to the development of formulations that are difficult to crush. The purpose of the present studies was to examine whether experienced prescription opioid abusers (individuals using prescription opioids for non-medical purposes regardless
Mark Rubino et al.
Journal of managed care pharmacy : JMCP, 17(5), 367-376 (2011-06-11)
The utilization of high-potency opioids is an important component of chronic pain management, and appropriate utilization of these medicines is a common concern of payers. Two of the most commonly prescribed oral long-acting opioids, oxycodone controlled-release (CR) and oxymorphone extended-release
Johannes H Bartholomaeus et al.
Expert opinion on drug delivery, 9(8), 879-891 (2012-06-14)
To prepare a polyethylene oxide-based tablet with high mechanical strength that would release an opioid for once- or twice-daily administration. This tablet would also create barriers against crushing and subsequent preparation steps for abuse and misuse that are not present
Irma H Benedek et al.
Drug design, development and therapy, 5, 455-463 (2011-12-14)
A formulation of crush-resistant extended-release opioids may deter abuse. The purpose of this study was to evaluate the bioequivalence of oxymorphone extended-release (Oxy-ER) and a crush-resistant formulation of oxymorphone extended-release (Oxy-CRF). In three open-label, randomized studies, healthy adults at a
View All Related Papers

Articles

Benefits of Ascentis Express Phenyl-Hexyl over Biphenyl for the Separation of Pain Management Opiates

Although both biphenyl and phenyl-hexyl phases can resolve these compounds, the former exhibits excellent peak shape and substantially less silanol-derived ion exchange activity.

Protocols

LC/MS (TOF) Analysis of Drugs and Their Glucuronide Metabolites in Urine on Titan™ C18 After Solid Phase Extraction (SPE) Using Supel™-Select SCX, β-Glucuronidase Enzyme Digestion

-THC solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material

UHPLC/MS for Drug Detection in Urine

Optimize β-glucuronidase hydrolysis for glucuronide metabolite analysis considering factors like time, temperature, pH, and enzyme concentration.

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service